Quantcast

Corvus Pharmaceuticals closer to submitting Investigational New Drug application for CPI-818

Corvus Pharmaceuticals’s study of its investigational small molecule T-cell signaling pathway inhibitorresults, indicated that orally-administered CPI-818 produced tumor regression in three of three companion dogs with spontaneous, naturally occurring T-cell lymphomas, without significant toxicity.

Read more